FCF YoY
-78.11%
OCF YoY
-78.83%
Capex YoY
+37.04%
FCF Conversion Δ
—
Free cash flow bridge for Revolution Medicines (RVMD) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: -$470M
FCF bridge breakdown for Revolution Medicines (RVMD) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | -$602M | — |
| Operating Cash Flow | -$466M | -99.2% |
| Capital Expenditure | -$3.86M | -0.8% |
| Free Cash Outflow | -$1.07B | — |
- Prior Free Cash Flow-$602M
- Operating Cash Flow-$466M
- Capital Expenditure-$3.86M
- Free Cash Outflow-$1.07B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
How this company returns cash to shareholders — buybacks, dividends, and stock splits.